Exelixis | EXEL - Assets


Exelixis reported $2.84B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Akebia Therapeutics USD 364.15M 18.56M Sep/2025
Amgen USD 90.59B 445M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Bayer EUR 104.21B 1.03B Sep/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
Eisai JPY 1.49T 48.22B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
Exelixis USD 2.84B 20.87M Dec/2025
Genmab DKK 6.46B 122M Jun/2025
Glaxosmithkline GBP 82.45B 23.19B Sep/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.34B 203M Dec/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Xencor USD 868.81M 10.61M Sep/2025